ITOS VS SIGA Stock Comparison

Performance

ITOS
10/100

ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.

SIGA
10/100

SIGA returned -45.09% in the last 12 months. Based on SPY's performance of -20.69%, its performance is below average giving it a score of 10 of 100.

Sentiment

ITOS
72/100

ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.

SIGA
66/100

SIGA had a bullish sentiment score of 66.19% across Twitter and StockTwits over the last 12 months. It had an average of 71.62 posts, 7,133.23 comments, and 80.87 likes per day.

Technicals

ITOS
14/100

ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

SIGA
18/100

SIGA receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

Earnings

ITOS
10/100

ITOS has missed earnings 5 times in the last 20 quarters.

SIGA

"Earnings" not found for SIGA

Profit

ITOS
31/100

Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.

SIGA
46/100

Out of the last 20 quarters, SIGA has had 10 profitable quarters and has increased their profits year over year on 6 of them.

Volatility

ITOS
40/100

ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

SIGA
46/100

SIGA has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Dividend

ITOS

"Dividend" not found for ITOS

SIGA
10/100

SIGA's most recent dividend was $0.45 per share, based on a share price of $4.98. It was a payout ratio of 99.71% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

iTeos Therapeutics, Inc. Common Stock Summary

Nasdaq / ITOS

Healthcare

Biotechnology

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

SIGA Technologies Inc. Summary

Nasdaq / SIGA

Healthcare

Drug Manufacturers - Specialty & Generic

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Power up your portfolio